期刊
CLINICAL LUNG CANCER
卷 23, 期 2, 页码 E137-E139出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2021.07.007
关键词
biomarkers; KRAS; STK11; Immunotherapy; Chemoimmunotherapy; Lung cancer
类别
We report a case of near-complete response to first-line pembrolizumab/platinum-doublet regimen in a patient with KRAS/STK11-mutant advanced lung adenocarcinoma. The study highlights that STK11 should not be used to select patients for PD(L)-1 blockade therapy until further prospective validation and clarification of interactions with other biomarkers such as TMB and PD-L1.
STK11 has been recently reported to be associated with primary resistance to PD-(L1)1 axis inhibitors. We report a case of near-complete response to first-line pembrolizumab/platinum-doublet regimen in a patient with KRAS/STK11-mutant advanced lung adenocarcinoma. Our case highlights that STK11 should not be used to select patients for PD(L)-1 blockade therapy, especially with used together with chemotherapy until further prospective validation and clarification of interactions with other biomarkers such as TMB and PD-L1. (C) 2021 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据